InvestorsHub Logo

doogdilinger

07/31/17 12:35 PM

#29008 RE: sprotje #29006

It's a category 3 HAP study...and CAT 3 nasal and oral abuse and liability studies are not even that costly.

Furthermore IPCI has already projected that they're close to attaining positive net income upon last months full commercialization of SeroquelXR by Mallinkrodt and expect to attain CFP status during their current Q3 or Q4 fiscal at the latest.

And I'd sure love to know how they're supposedly going to be able to sell DISCOUNT shares from their At-The-Market offering.

And lmao @ predictions of bankruptcy hahahahahahahaha